VC Fund Dossiers

This is Jerry Yang's personal piggy bank fund - no traditional LPs, which means faster decisions and unusual flexibility in check sizes, but also means they follow three strict anti-Yahoo rules: avoid consumer internet, invest early-stage only, and back only data-driven deep tech. The flat structure with just four investors means you get direct access to decision-makers, not junior associates. Jerry's China connections are legit - he's still on Alibaba's board and has deep Asia-Pacific relationships that most Silicon Valley funds can only dream of. The catch? They reportedly require distant companies to relocate headquarters to Silicon Valley for hands-on support - so if you're not willing to move, don't bother. With 251 investments generating 16 unicorns and 83 acquisitions including Slack and Okta, their hit rate speaks for itself.

American Express Ventures is the classic corporate VC play - they write decent checks but the real question is whether you want AmEx as a strategic partner. If your business could benefit from AmEx's merchant network, customer base, or payments infrastructure, they can be genuinely valuable beyond just capital. The team is professional and knows their lanes, but like most corporate VCs, they move slower than pure financial investors and every deal gets scrutinized through the lens of strategic fit. They're not going to lead your round or fight for you in a down market the way a traditional VC might, but they're solid co-investors if the strategic alignment makes sense. Don't expect them to be your primary champion.

Amino punches above their weight class with some genuinely impressive exits like Grammarly and strong portfolio companies like Webflow and Replit. They're particularly good at spotting technical talent early and have solid enterprise software instincts. However, their cross-border focus can be a double-edged sword - great if you're building for global markets, potentially limiting if you're purely domestic. The partners are operationally savvy and actually helpful post-investment, but they're not the biggest check writers and can be slower to make decisions than some founders expect.

Ampersand is the steady Eddie of healthcare investing - they know their lane and stick to it religiously. These guys have been doing healthcare growth deals since before it was cool and have genuine operational chops. They're not flashy or fast, but they're thorough and actually helpful post-investment. The catch? They move at healthcare industry speed (read: glacial) and their due diligence process can feel like getting a root canal. If you're a hot SaaS company looking for quick growth capital, look elsewhere. But if you're in healthcare services or HIT and want investors who actually understand your regulatory headaches and can help with acquisitions, they're solid.

Amplify is solid but unremarkable - they're the enterprise software equivalent of a reliable Honda Civic. They know their lane (B2B infrastructure) and stick to it, which means they won't waste your time if you're building consumer apps. Their partners have real operational experience, not just investment banking backgrounds, so they can actually help with product decisions. The downside? They're not exactly known for writing big checks or taking big swings. They're methodical, sometimes to a fault, and their brand recognition is middling compared to tier-one funds.

Amplitude is a solid regional player that's punching above its weight class, especially if you're Canadian or selling into the Quebec market. They're operationally savvy and won't waste your time with fluffy advice - expect real, actionable feedback. The downside? Limited brand recognition outside Canada can hurt with customer acquisition and follow-on rounds from top-tier US funds. They're genuinely helpful post-investment but don't expect them to open doors at Google or Microsoft the way a Sequoia would.

Angeleno Group is the energy transition OG - they were betting on clean tech before it was cool, literally founding the firm in 2001 when 'clean energy' wasn't even in most VCs' vocabulary. The founders are a compelling duo: Weiss brings legal/policy chops from white-shoe law firm O'Melveny and actual White House experience, while Tepper has serious finance credentials (grew a fund from $150M to $2B at Aetna). Their advisory board is genuinely impressive - Janet Yellen, Ernest Moniz, Frances Arnold - these aren't vanity adds, they're heavy hitters who signal serious conviction. In more than two decades, Tepper and Weiss' firm has invested in nearly 40 companies and has led or co-led funding totaling about $3 billion. But here's what matters for founders: they're sector-focused but stage-agnostic, which means they can follow you from growth through exit. The $10-30M check size is real money that moves needles.

ANIMO is still proving itself as a new fund but has solid operator-turned-investor partners with real domain expertise. They're not just another AI hype fund - the partners actually understand the industries they invest in and can provide genuine operational value. Mehta and Yoo bring legitimate network effects from their Eniac and a16z connections respectively. The Miami location might seem random, but they're genuinely building a presence in emerging tech hubs beyond Silicon Valley. Watch for how they handle their first major exits - that'll tell you if they can really deliver returns or if it's just good marketing.

Ankona is the scrappy fund that punches above its weight class by backing solid B2B software companies before they become obvious to bigger funds. David Keene and team have decent pattern recognition for enterprise software but aren't the first call for many hot deals. They're genuinely helpful post-investment and won't ghost you, which is refreshing. The downside? Limited dry powder means they can't always follow-on in later rounds, and their brand doesn't open as many doors as top-tier funds. Good choice if you want investors who actually answer emails and provide real operational help.

Anorak is the real deal for technical B2B founders - Volpi and Hamid both have serious enterprise chops and actually understand infrastructure. They move fast, write reasonable checks, and don't micromanage. The catch? They're extremely selective and prefer founders who can speak their technical language fluently. If you're building consumer or need hand-holding on go-to-market, look elsewhere. But if you're a technical founder with a genuinely differentiated B2B product, they're worth the pitch.

Anthem is one of those funds that keeps a surprisingly low profile for a firm in the crowded LA scene. They seem to actually focus on writing checks rather than building personal brands, which is either refreshing or concerning depending on how you look at it. The portfolio suggests they have decent deal flow and can get into competitive rounds, but the lack of public thought leadership makes it hard to gauge their true conviction areas. For founders, this could mean less ego-driven partnerships but also potentially less help with PR and network effects post-investment.

Anthos is the definition of a focused, disciplined fund that actually knows their lane and stays in it. Raj Kapoor and team have legitimate enterprise software chops and don't chase shiny objects or trendy sectors they don't understand. They're genuinely helpful on enterprise sales strategy and have real relationships with CISOs and CTOs who can be early customers. The downside? They're pretty conservative on valuations and won't get into bidding wars, so if you're hot and have multiple term sheets, they might not be your highest bidder. But if you want investors who will roll up their sleeves and help you build a real business rather than just pump up your next round, they're solid.

Anzu is a solid, no-nonsense B2B fund that actually knows the industries they invest in. Unlike funds that spray and pray across sectors, these guys have genuine domain expertise in healthcare, fintech, and supply chain software. John Freund's Bessemer pedigree shows in their disciplined approach to unit economics and scalability. They're not going to wow you with flashy PR or celebrity endorsements, but they'll roll up their sleeves and help you build a real business. The downside? They're not the biggest check writers, and if you're looking for consumer or deep tech, look elsewhere.

Aperture is the rare fund where the technical chops actually match the marketing. Aditya brings legitimate engineering credibility from Dropbox and Facebook, which matters when you're evaluating developer tools or infrastructure plays. Scott's operational experience shows up in their portfolio support - they actually help with go-to-market execution rather than just making intros. The Philadelphia base means less competition for deals but also a smaller local network. They move fast on technical diligence but can be tough on business model assumptions. Portfolio founders consistently mention their hands-on approach post-investment, though some note they can be overly involved in product decisions.

Applied Ventures is the strategic arm of a $60B semiconductor equipment giant, which means they have real money and genuine industry connections that can open doors. The good news: if you're building something that touches chip manufacturing, they actually understand the space and can provide real technical validation plus introductions to every major fab. The reality check: this is corporate venture capital at its most corporate - expect longer decision cycles, internal politics affecting your deal, and strategic considerations that may not align with pure financial returns. They're genuinely helpful for hardware startups needing manufacturing partnerships, but software companies often find the relationship less valuable than promised.

Ara Partners is one of the more pragmatic climate funds out there — they actually understand that industrial companies move slowly and care about ROI more than saving the planet. Their partners have real industrial experience, which is rare in this space where most climate VCs are ex-consultants who've never set foot in a factory. They're not chasing the latest shiny climate tech object; they focus on proven technologies that can actually scale in heavy industry. The downside? They're relatively new as a fund and their portfolio is still proving itself. If you're building something for manufacturing or heavy industry, they get the sales cycles and regulatory headaches better than most VCs.

Arboretum is a solid, if unspectacular, healthcare-focused fund that actually knows the space rather than just chasing healthcare as a hot sector. Tim Petersen and team have real operational chops and will roll up their sleeves to help with business development and strategic partnerships. The Michigan connection is real — they leverage University of Michigan resources and can help with talent and clinical partnerships. However, their check sizes are modest and they expect founders to be very metrics-driven from day one. Not the fund for moonshot science projects, but great for founders who want engaged partners who understand healthcare's unique challenges.

This isn't really a venture fund in the traditional sense — it's Wall Street guys applying institutional asset management to crypto with a side hustle in early-stage deals. Founded by Wall Street veterans who saw a lack of investable crypto products that meet institutional investor standards, Arca applies decades of asset management experience and superior risk management to their investment and product innovation arms. Their real business is running crypto hedge funds and launching blockchain-based financial products like their U.S. Treasury Fund. The venture investing feels more like strategic bets to support their broader ecosystem rather than dedicated venture capital. The firm's clear focus is on creating sophisticated crypto investment vehicles for institutional clients. This suggests a product-centric approach, prioritizing the technical and regulatory rigor needed to bring digital assets into mainstream finance. Arca is likely a good match for founders building in the FinTech space, particularly those focused on blockchain infrastructure or decentralized finance. If your company aims to serve institutional markets, their expertise could be valuable.

Arch is the real deal in life sciences - they've been doing this longer than almost anyone and have the exits to prove it. Their partners actually understand the science, not just the business model, which matters when you're betting on 10-year drug development timelines. They're patient capital with deep pockets and genuine operational expertise. The flip side? They're extremely selective and can be slow to move. If you're not Stanford/Harvard pedigreed or don't have a Nobel laureate on your team, getting their attention is tough. They also tend to take meaningful ownership stakes, so expect some control.

ARCH is the gold standard for biotech investing but they're not messing around with tourist entrepreneurs. They want founders who understand that building breakthrough science takes 7-10 years and $100M+ in capital. Nelsen has an almost mystical ability to spot winning biotech platforms early, but he'll grill you on the science until you cry. They're incredibly supportive if you make the cut - legendary for helping companies navigate FDA approval processes and building world-class management teams. Just don't expect quick exits or patience for pivoting away from hard science.

ARCH is the real deal for deep tech founders who actually have breakthrough science, not just another SaaS tool with AI sprinkled on top. They've been doing this since before 'deep tech' was a buzzword and have the scientific chops to understand what you're building. The flip side? They move slowly, do serious diligence, and won't invest unless they truly believe you're creating something fundamentally new. If you're looking for quick cash to scale a proven model, look elsewhere. But if you've got legitimate IP and need investors who won't panic when your clinical trial takes three years, ARCH is gold.

ARCH is the real deal for deep science and biotech - they've been doing this since before most VCs knew what DNA sequencing was. Bob Nelsen is genuinely one of the smartest biotech investors alive and the team has serious technical chops. They're patient capital that understands long R&D cycles, but they're also tough - they'll push you hard on milestones and scientific rigor. Not the fund for consumer apps or quick flips, but if you're building something that requires PhD-level science and 7-10 year timelines, they're gold standard. They do their homework and won't waste your time if the science doesn't check out.

ArcTern is one of the few genuinely dedicated cleantech funds in Canada, which means they actually understand the space instead of just chasing ESG buzzwords. Tom Rand knows his stuff but can overthink deals to death - expect multiple technical deep dives. They're patient capital which is great for hardware-heavy cleantech, but their check sizes are modest and they're not your go-to for quick decisions. Portfolio companies say they're supportive but not particularly hands-on post-investment. If you're building actual climate tech (not just SaaS with green marketing), they're worth the conversation.

This is a conviction-based fund with serious experience—50+ years combined, 90+ investments, $1B+ in realized returns. Phil Bronner gets genuine founder testimonials like 'one of the best investors I've worked with' from portfolio CEOs. They're actively deploying—8 investments in 2025 alone, with solid exits including 14 acquisitions and 1 IPO across portfolio. But they'll invest in anything that fits their thesis—even Kevin Durant's pickleball startup for $750K. They prefer to lead early rounds but are flexible enough to follow in later rounds for winners, and they actually mean 'all-in' with hands-on board participation.

Array is one of the few funds that actually gets developer tools and doesn't just throw around buzzwords. Shruti and Campbell have real technical chops and operational experience, which shows in their portfolio construction. They're not the biggest check writers, but they're genuinely helpful on product positioning and technical go-to-market for dev-focused companies. The downside? They're pretty narrow in their focus, so if you're not building for developers or technical buyers, you're probably not a fit. Also, being smaller means less firepower for major competitive rounds.

Arrington Capital is crypto royalty riding on Michael Arrington's TechCrunch fame, but here's what founders need to know: they're genuinely crypto-native since 2017, not tourists. The fund had a rough 2022 when they had to scrub their $100 million Anchor Yield Fund from their website after the Terra/UST collapse. This shows they'll take big swings but also demonstrates the kind of ecosystem-specific concentration risk that comes with their thesis-driven approach. Arrington XRP Capital operates as a fully crypto-denominated fund using XRP as its base currency for all transactions and leverages Ripple's infrastructure for faster cross-border settlements, while also acting as an active network participant by running validator nodes and hosting ecosystem events rather than just buying tokens. The firm combines Michael Arrington's Silicon Valley background and media influence with systematic trading capabilities through its merger with ByteSize Capital. The upside? Arrington's media connections can genuinely move markets and get you press coverage. The downside? In 2013, Harde defended Arrington publicly in the face of allegations of sexual and physical abuse by former girlfriends. While Heather has transitioned to strategic advisor, founders should know this fund operates with Silicon Valley old-school mentality.

Arthur Ventures is solid but unspectacular - they're the steady Eddie of midwest B2B investing. Finn and Larson know their market well and provide genuine operational value, especially for companies scaling outside coastal bubbles. They're not going to lead your Series A at a crazy valuation, but they won't ghost you when markets turn either. The trade-off: they can be conservative on check sizes and slower on decisions compared to coastal funds. Good choice if you want experienced partners who understand midwest business dynamics, but don't expect them to move at Silicon Valley speed.

Artiman is quietly one of the more competent enterprise-focused funds you haven't heard enough about. They have serious technical chops with Selina's engineering background and Umesh's enterprise investing track record. Their Snowflake and HashiCorp wins speak volumes about their ability to spot infrastructure winners early. They're genuinely helpful post-investment, especially on technical hiring and product strategy, but they're not going to coddle you or provide tons of hand-holding. If you're a technical founder building serious B2B infrastructure, they're worth the conversation.

ARTIS punches above its weight class in the enterprise AI space - they were early on some genuinely good companies like Domino and Cribl when others were still figuring out what MLOps meant. Mike Lazarus has solid technical judgment and doesn't just chase buzzwords. The downside? They're a smaller fund so follow-on capacity can be limited, and they can be pretty hands-on which some founders love but others find intrusive. They're genuine believers in the AI infrastructure thesis, not just tourists, which shows in their portfolio construction.

Ascend is solid but not spectacular - they're the reliable mid-tier fund that won't blow you away but probably won't screw you either. Their Microsoft/enterprise connections are real and valuable if you're selling to big companies. The partners know enterprise software cold, but they're not exactly lighting the world on fire with unicorn exits. They're methodical, process-driven investors who do their homework and can actually help with enterprise sales strategy. Not the sexiest brand name for your deck, but they show up and do the work.

Here's what founders actually say about working with At One: while they spend most of their time with other investors explaining the science behind their company, the At One team truly understands the technical fundamentals and quickly moves to helpful conversations about go-to-market and business issues. They're known for serious portfolio support with dedicated resources for talent, marketing, patent strategy, and manufacturing—particularly focused on helping companies scale manufacturing and achieve superior unit economics. Their secret weapon is four engineering EIRs with manufacturing backgrounds who help overcome common scale-up obstacles like building first-of-a-kind facilities and reducing CapEx/OpEx. The flip side? This is serious deep tech with long timelines—don't expect quick exits or SaaS-like growth curves.

Atlanta Ventures is one of the few legitimately founder-friendly funds in the Southeast. David Cummings' operator background shows - he actually gets product-market fit and will roll up his sleeves on go-to-market. They're not writing the biggest checks, but they're smart money that won't vanish when things get tough. The downside? They're geographically focused, so if you're not in their backyard, you might not get the full treatment. Their portfolio depth in B2B SaaS means they have real pattern recognition, but they can be conservative on newer categories.

Atlas is old-school VC done right in biotech — they actually understand the science and have the patience for long development cycles. Bruce Booth is genuinely one of the smartest biotech investors out there, but he's also quite opinionated and will push his views hard. They're great for founders who want strategic guidance and industry connections, less great if you want to be left alone to execute. Their digital health practice is newer and still finding its footing compared to their biotech chops. They move deliberately (sometimes too slowly for Silicon Valley standards) but when they commit, they really commit with follow-on capital and extensive support.

Gavin Baker is one of the most respected growth investors in the game, with a track record that speaks for itself from his Fidelity days. The guy doesn't chase fads - he finds exceptional companies and holds them through thick and thin. That said, Atreides is essentially Gavin's show, so you're betting on one person's judgment. He's incredibly thoughtful and has genuine operational insights, but the fund is still relatively new as an independent entity. If you can get him interested, he's the kind of investor who will stick with you through tough times and genuinely help you think through long-term strategy.

ATX VP is a solid regional fund that punches above its weight class. Jason Seats actually knows how to build companies, having done it himself, which shows in their portfolio support. They're not just check-writers - they roll up sleeves and help with real operational challenges. The Austin focus means less competition for deals but also means they really know the local ecosystem. Don't expect Silicon Valley-style valuations or ego stroking, but do expect practical advice and genuine partnership. They move fast on decisions and don't play games with term sheets.

Autotech is the rare mobility-focused fund that actually understands both the tech and the brutal realities of the auto industry. Their partners have real operational experience, not just consulting backgrounds, which matters when you're trying to sell to Ford or navigate DOT regulations. The flip side is they can be overly cautious about consumer-facing mobility plays and sometimes overthink the corporate development angle. They're genuinely helpful post-investment with introductions to OEMs and industry veterans, but don't expect them to move fast on decisions.

Avenir is the fund you call when you need serious operational help scaling from $10M to $50M ARR, not when you want strategic vision or early-stage hand-holding. They're former bankers and growth operators who actually know how to read a P&L and will push you hard on unit economics. Portfolio companies rave about their operational discipline but note they can be pretty demanding on metrics and reporting. If you're looking for patient capital or someone to validate your pivot ideas, look elsewhere. If you want someone to help you build a machine that prints money, these are your people.

Avid is the rare fund that actually understands what technical founders need - they've been there themselves. Tomer built Gusto from scratch and Shaun has serious technical chops from his quantum computing background and Sequoia experience. They're genuinely helpful on go-to-market for founders who can build great products but struggle with sales and marketing. Portfolio companies consistently praise their operational support. The downside? They're still relatively new as a fund, so their network isn't as deep as established players, and they can be selective to a fault.

Backstage is genuinely committed to backing underrepresented founders, but the execution can be uneven. Arlan is charismatic and well-connected but sometimes overpromises on support and follow-through. If you fit their thesis, they'll open doors others won't, but don't expect the same level of operational support as more established funds. The team dynamic has improved with Christie's addition. They're scrappy and founder-friendly, but fund construction means smaller checks and potentially less follow-on capital than you might need for scaling.

Arlan Hamilton built something genuinely important — a fund that actually backs underrepresented founders when others just talk about it. The mission is real and the access is unprecedented if you fit their thesis. But this isn't your typical Sand Hill Road operation. Expect more hands-on founder mentorship than traditional VC polish, and be prepared for a smaller check size than you might get elsewhere. Hamilton's unconventional background is both the fund's superpower and potential limitation depending on what kind of support you need. If you're looking for someone who genuinely gets the challenges of being an outsider founder, they're gold. If you need deep enterprise sales connections or traditional VC network effects, look elsewhere.

BCLS is the institutional life sciences money with serious firepower and a track record that speaks volumes. Their Cerevel exit to AbbVie for $8.7B delivered a 10x return on their $250M investment, and SpringWorks IPO'd in 2019 with them owning 17%. They've cracked the code on pharma carve-outs and spin-offs better than almost anyone. They just led a $300M investment in a new company built around Bristol Myers assets, following their successful playbook with Cerevel and SpringWorks. The downside? This is big money looking for big outcomes - if you're not swinging for billion-dollar exits, you're probably not their speed. They have the Bain pedigree and consulting DNA, so expect thorough due diligence and operational involvement.

BCV brings legitimate operational chops thanks to their Bain consulting DNA, but this can be a double-edged sword. They'll actually help you think through strategy and operations in ways most VCs can't, but expect lots of frameworks, decks, and process. They're particularly strong in enterprise software where their consulting background translates well to helping with sales and customer success. The flip side? They can be slow to move and sometimes over-engineer decisions that need speed. Their consumer bets have been more hit-or-miss lately as they lean into their enterprise strengths.

Baird Capital is the investment arm of a major investment bank, which cuts both ways. On the upside, they have incredible deal flow from Baird's banking relationships and can actually help with M&A when you're ready to exit. They're also not fundraising every few years like independent funds, so they're patient capital. The downside? They're not exactly known for taking big swings on unproven markets - they like profitable, predictable businesses that fit neat categories. Their sweet spot is being the growth capital for companies that are already working but need fuel to scale. Don't expect them to lead your Series A or get excited about your moonshot AI idea.

Ballistic is what happens when enterprise software VCs get really serious about cybersecurity. They actually understand the technical nuances and aren't just riding the security hype wave. Their partners have real operational experience and can open doors at large enterprises. The downside? They're highly selective and move slowly on deals outside their core thesis. If you're building anything security-adjacent but not pure-play cybersecurity, they'll probably pass quickly.

Balyasny Atlas brings serious institutional capital and hedge fund discipline to growth investing, which can be both blessing and curse. They have deep pockets and sophisticated financial analysis, but this isn't your typical VC relationship. They think like institutional investors first, venture partners second. Great for founders who want smart money with minimal drama and strong follow-on capacity, but don't expect them to roll up sleeves on product strategy or recruiting like traditional VCs. Their hedge fund DNA means they're numbers-driven and less tolerant of extended burn without clear progress metrics.

BAM is a solid, no-nonsense shop that actually knows how to build businesses, not just write checks. Their partners have real operational chops and will roll up their sleeves to help with everything from hiring to product strategy. They're not the flashiest name on your cap table, but they're the ones you'll actually want in the room when things get tough. The downside? They can be pretty hands-on, which some founders love and others find suffocating. They also tend to be conservative with valuations, so don't expect them to get into bidding wars.

BankTech is that rare fund that actually walks the walk - they're genuinely embedded in community banking with 100+ banks as LPs who use their portfolio companies operationally. Carey Ransom isn't just another VC; he's a battle-tested operator who's been through the startup grind 8 times and genuinely cares about founder success. The fund's secret sauce is their ecosystem approach - they facilitate real vendor contracts between their banks and startups, not just demo days. Their first exit (Adlumin) in just 3 years proves they can deliver returns. However, their hyper-focus on community banks means if you're building for enterprise banks or consumer fintech, look elsewhere.

Baroda Ventures flies under the radar with minimal public presence, which could be either refreshing or concerning depending on what you're looking for. Their website is sparse on details about partners, portfolio, or investment approach beyond generic messaging. For a Beverly Hills-based fund, they're surprisingly quiet on social media and industry events. This could mean they're either very selective and relationship-driven, or they're a smaller, newer fund still building their brand. The lack of visible portfolio companies or partner backgrounds makes it hard to assess their actual value-add or investment track record.

Base Ventures punches above its weight class thanks to Howie Liu's Airtable credibility and genuine operator insights. They're genuinely helpful on product strategy and have solid enterprise connections, but they're still building their reputation as investors versus operators. The fund is relatively small, so they pick their shots carefully and can give meaningful attention to portfolio companies. They understand B2B product-market fit better than most seed funds, but don't expect the same brand recognition or downstream connections as tier-1 VCs.

Base10 is solid but not flashy - they actually know enterprise software and have real operating experience. Their automation thesis is genuine, not just AI hype, and they tend to back technical founders building unsexy but profitable businesses. The partners are helpful post-investment and don't try to take credit for your success. However, they're not the fastest movers and can be overly analytical during diligence. If you're building B2B automation tools, they're worth talking to, but don't expect them to lead your round quickly.